CB 103

Drug Profile

CB 103

Alternative Names: CB-103

Latest Information Update: 29 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cellestia Biotech
  • Class Antineoplastics
  • Mechanism of Action Notch signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Haematological malignancies; Solid tumours

Most Recent Events

  • 05 Dec 2017 Phase-I/II clinical trials in Haematological malignancies (Late-stage disease, Second-line therapy or greater) in Switzerland (PO) after December 2017 (NCT03422679)
  • 05 Dec 2017 Phase-I/II clinical trials in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Switzerland (PO) after December 2017 (NCT03422679)
  • 03 Nov 2017 Swissmedic approves clinical trial application for a phase I/IIa trial in Solid tumours and haematological malignancies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top